Molecular Cancer Monitoring
Trovagene's breakthrough oncogene mutation monitoring tests provide new clinical insights for measuring therapeutic response, tracking the emergence of resistance markers, and detecting specific actionable mutations. Our technology isolates and analyzes cell-free tumor DNA in the urine rather than from the tumor tissue of cancer patients. This allows for frequent, large-volume sampling with a high degree of diagnostic sensitivity and patient convenience.
FIND OUT MORE ➤
State-of-the-Art Mutation Detection
Trovagene uses proprietary targeting and enrichment techniques, along with the most advanced diagnostic technology available, to provide commercial testing services through its CLIA-certified, CAP-accredited laboratory. This state-of-the-art facility leverages a strong foundation in basic research and the latest technologies for processing our novel diagnostics for the oncology community.
FIND OUT MORE ➤
Dynamic Diagnostic Technology Platform
Trovagene technology is enabling the development of non-invasive molecular diagnostic tests to detect, quantify and monitor genetic mutations that drive cancer dynamically over time. These groundbreaking discoveries are making possible a range of testing applications that can substantially enhance the mutation detection and cancer monitoring options available to physicians.
Cell-Free Nucleic Acids Offer New Insight
In the past, scientists believed that nucleic acids (DNA and RNA) were only found within cells. As detection equipment became more sensitive, fragments of cell-free nucleic acids (cfNAs)were found in blood plasma. Trovagene scientists were the first to make the simple yet remarkable discovery that these cfNAs filter through the kidneys and can also be detected in urine. Our proprietary ultra-short amplicon assays allow for the efficient detection and quantification of these fragments.